ST. LOUIS, Sept. 26, 2016 /PRNewswire/ -- The Simmons Law Firm filed suit Aug. 26 against Pfizer, Inc., on behalf of 71 women with healthy Body Mass Indexes alleging they developed type 2 diabetes as a result of taking Lipitor, a cholesterol-lowering drug manufactured by the pharmaceutical giant. The suit (Case No. 1322-CC09218) was filed in the 22nd Circuit Court of Missouri in the City of St. Louis after the application to consolidate the cases into a Federal Multidistrict Litigation was denied.
(Logo: http://photos.prnewswire.com/prnh/20130926/CL85566LOGO)
"We are looking forward to helping these and other women across the country have their day in court," said Shareholder and Pharmaceutical Department Head Trent Miracle. Simmons is a national litigation firm known for handling dangerous drug and device cases.
Lipitor, a statin, entered the market in the mid-1990s. It was designed to regulate the amount of cholesterol in the blood. Pfizer has spent hundreds of millions of dollars on marketing and advertising the drug.
The complaint alleges Pfizer did not conduct adequate studies or issue any warnings even though their internal data showed Lipitor placed women at an elevated risk of developing type 2 diabetes.
The Lipitor attorneys at the Simmons Firm are currently investigating claims from women diagnosed with type 2 diabetes after taking Lipitor.
About Simmons Browder Gianaris Angelides & Barnerd LLC
The Simmons Firm is a leading law firm in dangerous drug and medical device litigation. The Simmons Firm has experience in litigating complex medical matters and has taken a leadership role in standing up for individuals who have been injured by dangerous or defective drugs. The firm has recovered hundreds of millions of dollars for its pharmaceutical clients in cases involving Oxycontin, Yaz, Bextra and more. Learn more at www.simmonspharmalaw.com.
SOURCE Simmons Browder Gianaris Angelides & Barnerd LLC
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article